Top 5 Stock Picks of Eli Casdin’s Casdin Capital

2. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Casdin Capital’s Stake Value: $163,290,000
Percentage of Casdin Capital’s Portfolio: 7.32%
Number of Hedge Fund Holders: 38

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company that aims to discover, develop, and commercialize novel medicines consisting of ribonucleic acids. Cantor Fitzgerald analyst Olivia Brayer initiated coverage of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on July 12, assigning the company a ‘Neutral’ rating and a $175 price target.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) saw a decrease in hedge fund sentiment recently. In Q1 2022, 38 hedge funds reported bullish positions in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), compared to 39 funds in the prior quarter. Kurt Von Emster’s VenBio Select Advisor is one of the leading shareholders of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), with 1.30 million shares worth $212.28 million.

Casdin Capital initiated its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter of 2015, purchasing 60,000 shares. During Q1 2022, the hedge fund held 1 million shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), worth over $163.29 million, representing 7.32% of its investment portfolio.